Bills would ban drugmaker deals to delay cheap drugs

Generic-drug makers in the past year have dropped a record number of patent lawsuits against brand-name pharmaceutical companies in exchange for compensation to delay getting money-saving drugs to market.
Legislation that has recently gained momentum in Congress threatens to end such deals.
The House has passed a bill limiting [...]

Controversial ‘Pay For Delay’ Provision Attached To Financial Services Bill

Controversial legislation that would limit brand-name and generic drug makers from reaching deals to delay generic drug marketing was attached to a Senate appropriations subcommittee’s financial services spending bill on Tuesday, sources say. The measure has been briefly attached to several other bills over the past year, including health reform legislation, only to be dropped [...]

US sees jump in “pay-for-delay” drug settlements

Brand-name drug companies made a record 21 deals so far this fiscal year with generic firms that delayed production of cheaper generic drugs, the U.S. Federal Trade Commission told lawmakers on Tuesday.
The FTC is trying to crack down on so-called “pay-for-delay” settlements, highlighting that when generic versions [...]